Myelofibrosis with myeloid metaplasia: New developments in pathogenesis and treatment

Internal Medicine

Volumn 43, Issue 7, 2004, Pages 540-547

  Dingli, David ^a   Mesa, Ruben A ^a   Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

Author keywords

Myelofibrosis; Myeloid metaplasia; Myeloproliferative disorder

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BUSULFAN; CLADRIBINE; COLLAGEN; CYCLOPHOSPHAMIDE; CYTOKINE; DANAZOL; ERYTHROPOIETIN; ETANERCEPT; FLUOXYMESTERONE; HYDROXYUREA; MELPHALAN; OSTEOCALCIN; OSTEOPROTEGERIN; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; PREDNISONE; R 155777; THALIDOMIDE; THROMBOPOIETIN; TIPIFARNIB; TRANSCRIPTION FACTOR GATA 1; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN; VATALANIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANGIOGENESIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SMEAR; BONE MARROW; CACHEXIA; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC DISEASE; CIRCULATION; COMORBIDITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG TARGETING; ERYTHROCYTE TRANSFUSION; EXTRAMEDULLARY HEMATOPOIESIS; FIBROSIS; HUMAN; INFECTION COMPLICATION; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPHTHISIC ANEMIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OSTEOSCLEROSIS; PATHOGENESIS; PORTAL HYPERTENSION; PROGNOSIS; QUALITY OF LIFE; REVIEW; SPLENECTOMY; SPLENOMEGALY; STEM CELL; STROMA; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT PLANNING;

AGED; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 4444337990     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.540     Document Type: Review

References (92)

1. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 342: 1255-1265, 2000.
2. Koch CA, Li CY, Mesa RA, Tefferi A. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 78: 1223-1233, 2003.
3. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 78: 174-194, 2003.
4. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev 15: 121-131, 2001.
5. Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 102: 684-690, 1998.
6. Altura RA, Head DR, Wang WC. Long-term survival of infants with idiopathic myelofibrosis. Br J Haematol 109: 459-462, 2000.
7. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the UK. Hematol Oncol 15: 173-189, 1997.
8. Mesa RA, Silverstein MN, Jacobsen SJ, Wollan PC, Tefferi A. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted County Study, 1976-1995. Am J Hematol 61: 10-15, 1999.
9. Chaiter Y, Brenner B, Aghai E, Tatarsky I. High incidence of myeloproliferative disorders in Ashkenazi Jews in northern Israel. Leuk Lymphoma 7: 251-255, 1992.
10. Tsukamoto N, Morita K, Maehara T, et al. Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement. Br J Haematol 86: 253-258, 1994.
11. Ruutu T, Partanen S, Knuutila S. Clonal karyotype abnormalities in erythroid and granulocyte-monocyte precursors in polycythaemia vera and myelofibrosis. Scand J Haematol 31: 253-256, 1983.
12. Buschte M, Janssen JW, Drexler H, Lyon J, Anger B, Bartram CR. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia 2: 658-660, 1988.
13. Mesa RA, Hanson CA, Rajkumar SV, Schroeder G, Tefferi A. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 96: 3374-3380, 2000.
14. Castro-Malaspina H, Gay RE, Jhanwar SC, et al. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders. Blood 59: 1046-1054, 1982.
15. Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol 97: 441-448, 1997.
16. Rameshwar P, Denny TN, Stein D, Gascon P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. J Immunol 153: 2819-2830, 1994.
17. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 86: 419-431, 1995.
18. Wang JC, Chen C, Lou LH, Mora M. Blood thrombopoietin, IL-6 and IL-11 levels in patients with agnogenic myeloid metaplasia. Leukemia 11: 1827-1832, 1997.
19. Elliott M, Yoon SY, Kao P, Li CY, Tefferi A. Simultaneous measurment of serum thrombopoietin and expression of megakaryocyte c-Mpl with clinical and laboratory correlates for myelofibrosis with myeloid metaplasia. Eur J Haematol 68: 175-179, 2002.
20. Taksin AL, Couedic JPL, Dusanter-Fourt I, et al. Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood 93: 125-139, 1999.
21. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood 88: 402-409, 1996.
22. Yanagida M, Ide Y, Imai A, et al. The role of transforming growth factor-beta in PEG-rHuMGDF-induced reversible myelofibrosis in rats. Br J Haematol 99: 739-745, 1997.
23. Villeval JL, Cohensolal K, Tulliez M, et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood 90: 4369-4383, 1997.
24. Frey BM, Rafii S, Teterson M, Eaton D, Crystal RG, Moore MA. Adenovector-mediated expression of human thrombopoietin cDNA in immune-compromised mice: insights into the pathophysiology of osteomyelofibrosis. J Immunol 160: 691-699, 1998.
25. Schmitt A, Drouin A, Masse JM, Guichard J, Shagraoui H, Cramer EM. Polymorphonuclear neutrophil and megakaryocyte mutual involvement in myelofibrosis pathogenesis. Leuk & Lymphoma 43: 719-724, 2002.
26. + cell mobilization in idiopathic myelofobrosis. Blood 102: 147, 2003.
27. Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 100: 3495-3503, 2002.
28. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.
29. Chagraoui H, Tulliez M, Smayra T, et al. Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO. Blood 101: 2983-2989, 2003.
30. Bobik R, Hong Y, Breier G, Martin JF, Erusalimsky JD. Thrombopoietin stimulates VEGF release from c-Mpl-expressing cell lines and haematopoietic progenitors. FEBS Letters 423: 10-14, 1998.
31. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO Journal 16: 3965-3973, 1997.
32. Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematologica 108: 237-245, 2002.
33. Pevny L, Simon MC, Robertson E, et al. Erythroid differentiation in chimaeric mice blocked by a targeted mutation in the gene for transcription factor GATA-1. Nature 349: 257-260, 1991.
34. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 93: 2867-2875, 1999.
35. Vannucchi AM, Bianchi L, Cellai C, et al. Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1 (low) mice). Blood 100: 1123-1132, 2002.
36. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet 361: 1617-1620, 2003.
37. + hematopoietic progenitors from patients with idiopathic myelofibrosis. Blood 101: 5087-5088, 2003.
38. Vannucchi AM, Bianchi L, Migliaccio AR, et al. Reduced GATA-1 content in megakaryocytes of patients with idiopathic myelofibrosis. Blood 102: 663, 2003.
39. Tefferi A. Thrombopoietin expression and plasma concentrations in chronic myeloproliferative disorders. Leuk Res 27: 121-123, 2003.
40. Tefferi A. The forgotten myeloproliferative disorder: myeloid metaplasia. Oncologist 8: 225-231, 2003.
41. Miller JB, Testa JR, Lindgren V, Rowley JD. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis. Cancer 55: 582-591, 1985.
42. Trautmann U, Rubbert A, Gramatzki M, Henschke F, Gebhart E. Multiple chromosomal changes and karyotypic evolution in a patient with myelofibrosis. Cancer Genet Cytogenet 61: 6-10, 1992.
43. Reilly JT, Snowden JA, Spearing RL, et al. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 98: 96-102, 1997.
44. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 113: 763-771, 2001.
45. Benesch M, Deeg HJ. Hematopoietic cell transplantation for adult patients with myelodysplastic syndromes and myeloproliferative disorders. Mayo Clin Proc 78: 981-990, 2003.
46. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88: 1013-1018, 1996.
47. Cervantes F, Pereira A, Esteve J, et al. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 97: 635-640, 1997.
48. Maziarz RT, Mesa RA, Tefferi A. Allogeneic stem cell transplantation for chronic myeloproliferative disorders and myelodysplastic syndromes: The question is "when". Mayo Clin Proc 2003: 941-943, 2003.
49. Tefferi A. Anemia in adults: A contemporary approach to diagnosis. Mayo Clin Proc 78: 1274-1280, 2003.
50. Rosenthal N, Erf LA. Clinical observations on osteopetrosis and myelofibrosis. Arch Intern Med 71: 793-813, 1943.
51. Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 49: 308-313, 1982.
52. Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 85: 595-599, 2000.
53. Rodriguez JN, Martino ML, Dieguez JC, Prados D. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and metaanalytical approach. Haematologica 83: 616-621, 1998.
54. Hasselbalch HC, Clausen NT, Jensen BA. Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. Am J Hematol 70: 92-99, 2002.
55. Tefferi A, Elliot MA. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia. Blood 96: 4007, 2000.
56. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 78: 34-39, 2003.
57. Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78: 21-33, 2003.
58. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 117: 288-296, 2002.
59. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101: 2534-2541, 2003.
60. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41: 375-381, 1988.
61. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 44: 33-38, 1990.
62. Oishi N, Swisher SN, Troup SB. Busulfan therapy in myeloid metaplasia. Blood 15: 863-872, 1960.
63. Naqvi T, Baumann MA. Myelofibrosis: response to busulfan after hydroxyurea failure. Int J Clin Pract 56: 312-313, 2002.
64. Petti MC, Latagliata R, Spadea T, et al. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 116: 576-581, 2002 (Erratum in: Br J Hematol 117: 1002, 2002).
65. Tefferi A, Silverstein MN, Li CY. 2-Chlorodeoxyadenosine treatment after splenectomy in patients who have myelofibrosis with myeloid metaplasia. Br J Haematol 99: 352-357, 1997.
66. Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b-feasibility and efficacy. Cancer 83: 1205-1213, 1998.
67. Barosi G, Liberato LN, Costa A, et al. Induction and maintenance alpha-interferon therapy in myelofibrosis with myeloid metaplasia. Eur J Haematol Suppl 52: 12-14, 1990.
68. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. Blood 97: 1896, 2001.
69. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 95: 2226-2233, 2000.
70. Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 91: 3630-3636, 1998.
71. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 120: 801-808, 2001.
72. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 103: 505-511, 1998.
73. Coates GG, Eisenberg B, Dail DH. Tc-99m sulfur colloid demonstration of diffuse pulmonary interstitial extramedullary hematopoiesis in a patient with myelofibrosis. A case report and review of the literature. Clin Nucl Med 19: 1079-1084, 1994.
74. Houck WA, Mesa RA, Tefferi A. Antemortem presentation and management of non-hepatosplenic extramedullary hematopoiesis in myelofibrosis with myeloid metaplasia. Blood 96: 747a, 2000.
75. Bartlett RP, Greipp PR, Tefferi A, Cupps RE, Mullan BP, Trastek VF. Extramedullary hematopoiesis manifesting as a symptomatic pleural effusion. Mayo Clin Proc 70: 1161-1164, 1995.
76. Marcos E, Adnot S, Pham MH, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168: 487-493, 2003.
77. Mitani Y, Mutlu A, Russell JC, Brindley DN, DeAlmeida J, Rabinovitch M. Dexfenfluramine protects against pulmonary hypertension in rats. J Appl Physiol 93: 1770-1778, 2002.
78. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 118: 813-816, 2002.
79. Steensma DP, Mesa RA, Li CY, Gray L, Tefferi A. Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: results of a pilot study. Blood 99: 2252-2254, 2002.
80. Mesa RA, Tefferi A. Survival and outcomes to therapy in leukemic transformation of myelofibrosis with myeloid metaplasia: a single institution experience with 91 patients. Blood 102: 917a, 2003.
81. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93: 2831-2838, 1999.
82. Deeg HJ, Gooley TA, Flowers MED, et al. Allogeneic hematopoietic stem cell transplantation for myelofobrosis. Blood 102: 3912-3918, 2003.
83. Li Z, Gooley T, Applebaum FR, Deeg HJ. Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. Blood 97: 2180-2181, 2001.
84. Guardiola P, Esperou H, Cazals-Hatem D, et al. Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia. French Society of Bone Marrow Transplantation. Br J Haematol 98: 1004-1009, 1997.
85. Deeg HJ, Appelbaum FR. Stem-cell transplantation for myelofibrosis. N Engl J Med 344: 775-776, 2001.
86. Anderson JE, Sale G, Appelbaum FR, Chauncey TR, Storb R. Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. Br J Haematol 98: 1010-1016, 1997.
87. Devine SM, Hoffman R, Verma A, et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 99: 2255-2258, 2002.
88. Anderson JE, Tefferi A, Craig F, et al. Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis, Blood 98: 586-593, 2001.
89. Tefferi A, Mesa RA, Gray LA, et al. Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia. Blood 99: 3854-3856, 2002.
90. De Angelo DJ, Soiffer RJ, Galinisky I, et al. Imatinib mesylate (Gleevec) for patients with chronic idiopathjic myelofibrosis (CIM): A phase II trial. Blood 102: 146a, 2003.
91. Mesa RA, Camoriano, JK, Geyer SM, et al. A Phase 2 consortium (P2C) trial of R115777 (Zarnestra) in myelofibrosis with myeloid metaplasia: interim analysis of 18 patients. Blood 102: 922a, 3428, 2003.
92. Giles FJ, List AF, Roboz GJ, et al. Phase I/II study of PTK787/ZK222584 (PTK/ZZ), a novel, oral VEGF-receptor inhibitor, in patients with myelofibrosis with myeloid metaplasia. Brood 102: 922a, 2003.